AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
167.76
+1.19 (0.71%)
At close: Nov 20, 2024, 4:00 PM
167.68
-0.08 (-0.05%)
After-hours: Nov 20, 2024, 7:52 PM EST
AbbVie Revenue
AbbVie had revenue of $14.46B in the quarter ending September 30, 2024, with 3.83% growth. This brings the company's revenue in the last twelve months to $55.53B, up 0.72% year-over-year. In the year 2023, AbbVie had annual revenue of $54.32B, down -6.44%.
Revenue (ttm)
$55.53B
Revenue Growth
+0.72%
P/S Ratio
5.34
Revenue / Employee
$1,110,660
Employees
50,000
Market Cap
296.46B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher | 42.37B |
Abbott Laboratories | 41.22B |
Eli Lilly | 40.86B |
ABBV News
- 22 hours ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 1 day ago - Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice - Business Wire
- 2 days ago - High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy - Seeking Alpha
- 3 days ago - AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - PRNewsWire
- 6 days ago - AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations - PRNewsWire
- 7 days ago - Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects - Seeking Alpha
- 8 days ago - AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
- 8 days ago - AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say - Market Watch